RAS Interaction with PI3K: More Than Just Another Effector Pathway
Open accessThe DOI matches its Crossref record; 205 of the 206 references it cites were found in a registry or an index.
Abstract
RAS PROTEINS ARE SMALL GTPASES KNOWN FOR THEIR INVOLVEMENT IN ONCOGENESIS: around 25% of human tumors present mutations in a member of this family. RAS operates in a complex signaling network with multiple activators and effectors, which allows them to regulate many cellular functions such as cell proliferation, differentiation, apoptosis, and senescence. Phosphatidylinositol 3-kinase (PI3K) is one of the main effector pathways of RAS, regulating cell growth, cell cycle entry, cell survival, cytoskeleton reorganization, and metabolism. However, it is the involvement of this pathway in human tumors that has attracted most attention. PI3K has proven to be necessary for RAS-induced transformation in vitro, and more importantly, mice with mutations in the PI3K catalytic subunit p110α that block its ability to interact with RAS are highly resistant to endogenous oncogenic KRAS-induced lung tumorigenesis and HRAS-induced skin carcinogenesis. These animals also have a delayed development of the lymphatic vasculature. Many PI3K inhibitors have been developed that are now in clinical trials. However, it is a complex pathway with many feedback loops, and interactions with other pathways make the results of its inhibition hard to predict. Combined therapy with another RAS-regulated pathway such as RAF/MEK/ERK may be the most effective way to treat cancer, at least in animal models mimicking the human disease. In this review, we will summarize current knowledge about how RAS regulates one of its best-known effectors, PI3K.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Network analysis of the several driver mutation genes, including KMT2D138, PIK3CA139, PTEN140, and IDH1141, that regulate signaling and metabolic pathways in KRAS-driven cancers, connects them to oncogenic RAS (Fig 4c).”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [138]
The cited source says what the claim attributes to it.
In the citing paper
“Oncogenic KRAS signaling also involves PI3K-AKT-mTOR, via the interaction with the catalytic subunits of PI3K (78–80).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [78]
The cited source says what the claim attributes to it.
In the citing paper
“An additional layer of complexity is the cross-regulation between the two pathways with ERK signaling feeding into several nodes of PI3K/mTOR such as its phosphorylation of TSC236–38.”
From Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer (2024) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Li, W., Zhu, T., & Guan, K.-L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405730200 · Cited by 78
RetractedMutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor
Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., & Greenberg, M. E. (1999) · Cell · doi:10.1016/s0092-8674(00)80595-4 · Cited by 5,594
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Research works printed but not linked: 1
- [5]5. Wolfman A, Macara IG. A cytosolic protein catalyzes the release of GDP from p21ras. Science. 1990;248:67-9 [DOI] [PubMed] [Google Scholar]
Cited by
Items 201–300 of 764
Monica, S. L., Minari, R., Cretella, D., Bonelli, M. A., Fumarola, C., Cavazzoni, A., Galetti, M., Digiacomo, G., Riccardi, F., Petronini, P. G., et al. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00669-x · Cited by 46
Liu, X., Fan, Y., Du, L., Mei, Z., & Fu, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.665102 · Cited by 49
“And PI3K/AKT signaling pathway is active in cells infiltrating inflamed human colon tissue via the participation of PTEN, GSK3B and mTOR, which may lead to over-transcription of downstream target genes, proliferation of intestinal epithelial cells, and even dysplasia and cancerization (Castellano and Downward, 2011; M…”
BackgroundSesquiterpene Lactones as Promising Candidates for Cancer Therapy: Focus on Pancreatic Cancer
Laurella, L. C., Mirakian, N. T., Garcia, M. N., Grasso, D., Sülsen, V. P., & Papademetrio, D. L. (2022) · Molecules · doi:10.3390/molecules27113492 · Cited by 43
Roper, J., Sinnamon, M. J., Coffee, E. M., Belmont, P. J., Keung, L., Richard, L. G., Wang, W. V., Faber, A. C., Yun, J., Yilmaz, Ö. H., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.02.018 · Cited by 44
Larive, R. M., Moriggi, G., Menacho-Márquez, M., Cañamero, M., de Álava, E., Alarcón, B., Dosil, M., & Bustelo, X. R. (2014) · Nature Communications · doi:10.1038/ncomms4881 · Cited by 48
Nussinov, R., Tsai, C.-J., Muratcioglu, S., Jang, H., Gursoy, A., & Keskin, O. (2015) · Expert Review of Proteomics · doi:10.1586/14789450.2015.1100079 · Cited by 42
Inhibition of mTORC2 component RICTOR impairs tumor growth in pancreatic cancer models
Schmidt, K. M., Hellerbrand, C., Ruemmele, P., Michalski, C. W., Kong, B., Kroemer, A., Hackl, C., Schlitt, H. J., Geissler, E. K., & Lang, S. A. (2017) · Oncotarget · doi:10.18632/oncotarget.15524 · Cited by 46
“Mutations in the PI3K/AKT/mTOR pathway are not a frequently reported alteration in PDAC, whereas the Ras oncogene is mutated in over 90% of PDAC patients [3, 18].”
BackgroundIn-silico design of peptide inhibitors of K-Ras target in cancer disease
Ghufran, M., Rehman, A. U., Shah, M., Ayaz, M., Ng, H. L., & Wadood, A. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1704880 · Cited by 43
Wagstaff, E. L., Berzal, A. H., Boon, C. J. F., Quinn, P. M. J., ten Asbroek, A. L. M. A., & Bergen, A. A. B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137081 · Cited by 52
“The kinase pathways involved in non-canonical signaling interact closely with each other, with Ras also activating the PI3K-Akt signaling pathway (Figure 3, PI3K-mTOR) [36].”
BackgroundGalal, M. A., Alouch, S. S., Alsultan, B. S., Dahman, H., Alyabis, N. A., Alammar, S., & Aljada, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241915006 · Cited by 50
“It is noteworthy to mention that RAS activation also activates the PI3k pathway by activating p110 independently of p85 [129].”
BackgroundTargeted treatments for vascular malformations: current state of the art
Seront, E., Hermans, C. R. J. R., Boon, L. M., & Vikkula, M. (2024) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.07.013 · Cited by 51
Delving into somatic variation in sporadic melanoma
Walia, V., Mu, E. W., Lin, J. C., & Samuels, Y. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2012.00976.x · Cited by 41
“The RAF family of serine ⁄ threonine kinases includes ARAF, BRAF, and CRAF, which activate mitogen-activated protein kinase (MAPK) kinase (MKK) that phosphorylates and induces activation of ERK ⁄ MAPK (Castellano and Downward, 2011).”
BackgroundInfluentialHamida, S. B., Neasta, J., Lasek, A. W., Kharazia, V., Zou, M. E., Carnicella, S., Janak, P. H., & Dorit Ron, A. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.2846-12.2012 · Cited by 40
“Like other members of the p21Ras family, once activated, H-Ras stimulates downstream signaling cascades including the phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT) and the mitogenactivated protein kinase (MAPK) pathways (Moodie et al., 1993; Orban et al., 1999; Castellano and Downward, 2011).”
BackgroundZhao, H., Wang, J., Jiang, H.-R., Chen, Z.-P., & To, S. S. T. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0356-5 · Cited by 48
“Combination therapy targeting PI3K/Akt pathway and Ras-mediated MAPK pathway may exert synergism for cancer treatment [36, 37].”
BackgroundOmega-3 Fatty Acids Prevent Early Pancreatic Carcinogenesis via Repression of the AKT Pathway
Ding, Y., Mullapudi, B., Torres, C., Mascariñas, E., Mancinelli, G. E., Diaz, A. M., McKinney, R. D., Barron, M. R., Schultz, M., Heiferman, M. J., et al. (2018) · Nutrients · doi:10.3390/nu10091289 · Cited by 46
aPKC controls endothelial growth by modulating c-Myc via FoxO1 DNA-binding ability
Riddell, M. R., Nakayama, A., Hikita, T., Mirzapourshafiyi, F., Kawamura, T., Pasha, A., Li, M., Masuzawa, M., Looso, M., Steinbacher, T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07739-0 · Cited by 43
Lipid-dependent Akt-ivity: where, when, and how
Siess, K. M., & Leonard, T. A. (2019) · Biochemical Society Transactions · doi:10.1042/bst20190013 · Cited by 43
Ras assemblies and signaling at the membrane
Nussinov, R., Tsai, C.-J., & Jang, H. (2020) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2020.01.009 · Cited by 41
Frank, K. J., Mulero-Sánchez, A., Berninger, A., Ruiz-Cañas, L., Bosma, A., Görgülü, K., Wu, N., Diakopoulos, K. N., Kaya-Aksoy, E., Ruess, D. A., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100815 · Cited by 40
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer
Federico, A. D., Ricciotti, I., Favorito, V., Michelina, S. V., Scaparone, P., Metro, G., Giglio, A. D., Pecci, F., Lamberti, G., Ambrogio, C., et al. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01436-y · Cited by 47
Therapeutic implications of targeting the PI3Kinase/AKT/mTOR signaling module in melanoma therapy.
Jazirehi, A. R., Wenn, P. B., & Damavand, M. (2012) · Europe PMC (PubMed Central) · Cited by 54
Jiwani, S. S., Wang, Y., Dowd, G. C., Gianfelice, A., Pichestapong, P., Gavicherla, B., VanBennekom, N., & Ireton, K. (2011) · Infection and Immunity · doi:10.1128/iai.06082-11 · Cited by 44
Keller, R., Klein, M., Thomas, M., Dräger, A., Metzger, U., Templin, M. F., Joos, T. O., Thasler, W. E., Zell, A., & Zanger, U. M. (2016) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004431 · Cited by 43
Sur8/Shoc2 promotes cell motility and metastasis through activation of Ras-PI3K signaling
Kaduwal, S., Jeong, W.-J., Park, J.-C., Lee, K. H., Lee, Y.-M., Jeon, S.-H., Lim, Y.-B., Min, D. S., & Choi, K.-Y. (2015) · Oncotarget · doi:10.18632/oncotarget.5173 · Cited by 40
“The activated Ras-Raf-ERK cascade is implicated in the activation of various target genes controlling cellular proliferation, differentiation, and transformation [3], as well as cell motility [4, 5].”
BackgroundResult5-O-Acetyl-Renieramycin T from Blue Sponge Xestospongia sp. Induces Lung Cancer Stem Cell Apoptosis
Chantarawong, W., Chamni, S., Suwanborirux, K., Saito, N., & Chanvorachote, P. (2019) · Marine Drugs · doi:10.3390/md17020109 · Cited by 44
Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
Singh, K., Lin, J., Lecomte, N., Mohan, P., Gokce, A., Sanghvi, V. R., Jiang, M., Grbovic-Huezo, O., Burčul, A., Stark, S. G., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2929 · Cited by 39
“Accordingly, PDACs show increased levels of mRNA translation and mediated through activation of MAPK, PI3K-AKTmTOR signals, NRF2, and MYC (18-20).”
BackgroundInfluentialVasjari, L., Bresan, S., Biskup, C. U., Pai, G. M., & Rubio, I. (2019) · Cell Cycle · doi:10.1080/15384101.2018.1560205 · Cited by 42
Mitotic Poisons in Research and Medicine
Škubník, J., Jurášek, M., Ruml, T., & Rimpelová, S. (2020) · Molecules · doi:10.3390/molecules25204632 · Cited by 44
Duan, S., Moro, L., Qu, R., Simoneschi, D., Cho, H., Jiang, S., Zhao, H., Chang, Q., de Stanchina, E., Arbini, A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109870 · Cited by 41
“Previous studies have demonstrated the existence of an ERK mediated negative feedback signal on both RAS/MEK/ERK and RAS/PI3K/AKT pathways (Castellano and Downward, 2011; Kodaki et al., 1994; Lake et al., 2016; Lito et al., 2013; Manning and Toker, 2017; Mendoza et al., 2011; Rodriguez-Viciana et al., 1994; Turke et…”
BackgroundBelmont, P. J., Jiang, P., McKee, T. D., Xie, T., Isaacson, J., Baryla, N. E., Roper, J., Sinnamon, M. J., Lee, N. V., Kan, J. L. C., et al. (2014) · Science Signaling · doi:10.1126/scisignal.2005516 · Cited by 41
“KRAS is directly implicated in the simplified linear RAS–RAF–MEK (mitogen-activated or extracellular signal–regulated protein kinase kinase)– ERK (extracellular signal–regulated kinase) signaling axis, as well as the PI3K (phosphatidylinositol 3-kinase)–mTOR (mechanistic target of rapamycin) signaling axis (26).”
BackgroundCombined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer
Kitai, H., Choi, P. H., Yang, Y. C., Boyer, J. A., Whaley, A., Pancholi, P., Thant, C., Reiter, J., Chen, K., Markov, V., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50063-z · Cited by 41
Methylglyoxal Scavengers Resensitize KRAS-Mutated Colorectal Tumors to Cetuximab
Bellier, J., Nokin, M.-J., Caprasse, M., Tiamiou, A., Blomme, A., Scheijen, J. L., Koopmansch, B., MacKay, G. M., Chiavarina, B., Costanza, B., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.012 · Cited by 38
D‐1553: A novel KRASG12C inhibitor with potent and selective cellular and in vivo antitumor activity
Shi, Z., Weng, J., Niu, H., Yang, H., Liu, R., Weng, Y., Zhu, Q., Zhang, Y., Tao, L., Wang, Z., et al. (2023) · Cancer Science · doi:10.1111/cas.15829 · Cited by 38
Dysregulated long non-coding RNAs in the temporal lobe epilepsy mouse model
Jang, Y., Moon, J., Lee, S., Jun, J. S., Lim, J., Lim, J., Park, B.-S., Yu, J.-S., Park, D.-K., Yang, A. R., et al. (2018) · Seizure · doi:10.1016/j.seizure.2018.04.010 · Cited by 38
Ruicci, K. M., Pinto, N. C., Khan, M. I., Yoo, J., Fung, K., MacNeil, S. D., Mymryk, J. S., Barrett, J. W., & Nichols, A. C. (2018) · Oral Oncology · doi:10.1016/j.oraloncology.2018.07.010 · Cited by 40
Receptor tyrosine kinase-Ras-PI 3 kinase-Akt signaling network in glioblastoma multiforme
Tuncel, G., & Kalkan, R. (2018) · Medical Oncology · doi:10.1007/s12032-018-1185-5 · Cited by 41
Holter, M. C., Hewitt, L. T., Koebele, S. V., Judd, J. M., Xing, L., Bimonte‐Nelson, H. A., Conrad, C. D., Araki, T., Neel, B. G., Snider, W. D., et al. (2019) · PLoS Genetics · doi:10.1371/journal.pgen.1008108 · Cited by 42
Sun, X., Ge, X., Xu, Z., & Chen, D. (2019) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14762 · Cited by 38
The recent progress and therapy in endometriosis-associated ovarian cancer
Su, K., Wang, P., Yu, M.-H., Chang, C.-M., & Chang, C. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000262 · Cited by 43
Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer
Cirone, P., Andresen, C. J., Eswaraka, J. R., Lappin, P. B., & Bagi, C. M. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2376-1 · Cited by 39
“Although activated KRAS can bind to and activate the p110α subunit of PI3K, resulting in the activation of downstream cellular functions [20, 21], we reported that bladder cancer cell lines are less sensitive to the MEK inhibitor PD-0325901 (hereafter PD901) when bearing mutations activating PI3K/AKT/mTOR either direc…”
BackgroundGaur, S., Chen, L., Ann, V., Lin, W., Wang, Y., Chang, V. H. S., Hsu, N. Y., Shia, H.-S., & Yen, Y. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-21 · Cited by 37
“PIP3, in turn, binds the pleckstrin homology (PH) domain of Akt/PKB, stimulating its kinase activity, resulting in the phosphorylation of a host of other proteins that affect cell growth, cell cycle entry, and cell survival [42,46].”
BackgroundMathew, M. P., Tan, E., Saeui, C. T., Bovonratwet, P., Sklar, S., Bhattacharya, R., & Yarema, K. J. (2016) · Oncotarget · doi:10.18632/oncotarget.11582 · Cited by 35
“Halilovic E, She QB, Ye Q, Pagliarini R, Sellers WR, Solit DB and Rosen N. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.”
BackgroundInfluentialWan, X., Wang, A.-Q., Cao, J., Dong, Z.-C., Li, N., Yang, S., Sun, M., Li, Z., & Luo, S.-X. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i7.808 · Cited by 41
Dorsal ruffles enhance activation of Akt by growth factors
Yoshida, S., Pacitto, R., Sesi, C., Kotula, L., & Swanson, J. A. (2018) · Journal of Cell Science · doi:10.1242/jcs.220517 · Cited by 36
“…synthesized by PI3K within CDR may be retained there by the diffusion barrier, allowing positive feedback stimulation of PI3K by PIP3, which could be mediated by Ras, Rac or the adapter protein Gab1 (Rodrigues et al., 2000, Castellano and Downward, 2011, Fritsch et al., 2013, Ding et al., 2015).”
BackgroundMetabolic Reprogramming: A Friend or Foe to Cancer Therapy?
McCann, C. K., & Kerr, E. M. (2021) · Cancers · doi:10.3390/cancers13133351 · Cited by 37
“KRAS has also been linked significantly to driving resistance to apoptosis through the modulation of key apoptotic gene expression [60], and by enhancing pro-survival signalling via ERK/PI3K networks [61,62].”
BackgroundMechanistic Insights of Thyroid Cancer Progression
Leandro-Garcia, L. J., & Landa, I. (2023) · Endocrinology · doi:10.1210/endocr/bqad118 · Cited by 42
A clinical perspective on the role of chronic inflammation in gastrointestinal cancer
Alguel, H., & Rasch, S. (2014) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s43457 · Cited by 40
The Structural Basis of the Farnesylated and Methylated KRas4B Interaction with Calmodulin
Jang, H., Banerjee, A., Marcus, K., Makowski, L., Mattos, C., Gaponenko, V., & Nussinov, R. (2019) · Structure · doi:10.1016/j.str.2019.08.009 · Cited by 35
“PI3Kα produces phosphatidylinositol (3,4,5)-trisphosphate (PIP3), which stimulates the PI3Kα/Akt/mammalian target of rapamycin pathway, regulating cell growth and survival, cytoskeleton reorganization, and metabolism (Castellano and Downward, 2011).”
BackgroundHemispherical Pediatric High-Grade Glioma: Molecular Basis and Therapeutic Opportunities
Haase, S., Núñez, F. M., Gauss, J. C., Thompson, S., Brumley, E. K., Lowenstein, P. R., & Castro, M. G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249654 · Cited by 35
Implications of Akt2/Twist crosstalk on breast cancer metastatic outcome
Pereira, L. P., Horta, S., Mateus, R., & Videira, M. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.06.010 · Cited by 36
Graziani, G., Artuso, S., Luca, A. D., Muzi, A., Rotili, D., Scimeca, M., Atzori, M. G., Ceci, C., Mai, A., Leonetti, C., et al. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.03.004 · Cited by 34
Castro, M. A., Rodenak‐Kladniew, B., Massone, A. R., Polo, M. P., de Bravo, M. M. G., & Crespo, R. (2018) · Food & Function · doi:10.1039/c7fo01912b · Cited by 37
Will Kinase Inhibitors Make it as Glioblastoma Drugs?
Mellinghoff, I. K., Schultz, N. D., Mischel, P. S., & Cloughesy, T. F. (2011) · Current topics in microbiology and immunology · doi:10.1007/82_2011_178 · Cited by 40
“Once activated, they phosphorylate and activate mitogen-activated protein kinase kinase (MAPKK or MEK) that, in turn, phosphorylates and activates extracellular signal-regulated kinases 1 and 2 (ERK1/2) (Castellano and Downward 2011; Shaw and Cantley 2006).”
BackgroundAkt scaffold proteins: the key to controlling specificity of Akt signaling
Bao, F., Hao, P., An, S., Yang, Y., Liu, Y., Hao, Q., Ejaz, M., Guo, X., & Xu, T. (2021) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00146.2020 · Cited by 36
Salem, M. M., Gerges, M. N., & Noser, A. A. (2022) · Scientific Reports · doi:10.1038/s41598-022-26571-7 · Cited by 38
NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation
Eisfeld, A., Schwind, S., Hoag, K. W., Walker, C. J., Liyanarachchi, S., Patel, R. K., Huang, X., Markowitz, J., Duan, W., Otterson, G. A., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1401727111 · Cited by 34
Sheffels, E., Sealover, N. E., Theard, P. L., & Kortum, R. L. (2019) · Small GTPases · doi:10.1080/21541248.2019.1611168 · Cited by 31
“cells in order for them to grow in an anchorageindependent environment and to invade and metastasize [34,35].”
BackgroundRas, PI3K and mTORC2 – three's a crowd?
Smith, S. F., Collins, S. E., & Charest, P. G. (2020) · Journal of Cell Science · doi:10.1242/jcs.234930 · Cited by 37
SOS2 Comes to the Fore: Differential Functionalities in Physiology and Pathology
Baltanás, F. C., García‐Navas, R., & Santos, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126613 · Cited by 32
“Furthermore, downstream RAS signaling through phosphoinositide 3-kinase (PI3K) has also been shown to have an essential role in processes such as cell survival, cytoskeleton reorganization, cell motility or invasiveness, among others [60].”
BackgroundMolecular inhibition of RAS signalling to target ageing and age-related health
Laskovs, M., Partridge, L., & Slack, C. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049627 · Cited by 41
“PI3K then phosphorylates phosphatidylinositol (4,5)-bisphosphate (PIP2) to form phosphatidylinositol (1,4,5)-triphosphate (PIP3) at the inner surface of the plasma membrane (Boucher et al., 2014).”
BackgroundInfluentialCyclophilin D counteracts P53-mediated growth arrest and promotes Ras tumorigenesis
Bigi, A., Beltrami, E., Trinei, M., Stendardo, M., Pelicci, P. G., & Giorgio, M. (2016) · Oncogene · doi:10.1038/onc.2016.42 · Cited by 32
RAS Function in cancer cells: translating membrane biology and biochemistry into new therapeutics
Kattan, W. E., & Hancock, J. F. (2020) · Biochemical Journal · doi:10.1042/bcj20190839 · Cited by 36
Liu, L., Dai, X., Yin, S., Liu, P., Hill, E. G., Wei, W., & Gan, W. (2022) · Science Signaling · doi:10.1126/scisignal.abh2290 · Cited by 29
“RAS may also promote mTORC2 kinase activity through the PI3K pathway (67).”
BackgroundFluvastatin Inhibits HMG-CoA Reductase and Prevents Non–Small Cell Lung Carcinogenesis
Zhang, T., Bai, R., Wang, Q., Wang, K., Li, X., Liu, K., Ryu, J., Wang, T., Chang, X., Ma, W., et al. (2019) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-19-0211 · Cited by 31
“Activated Ras recruits serine/threonine kinases of the RAF family to the plasma membrane and constitutively triggers the Braf/MEK/ERK1/2 (37) and PI3-K pathways (38).”
BackgroundCell growth and the cell cycle: New insights about persistent questions
Øvrebø, J. I., Ma, Y., & Edgar, B. A. (2022) · BioEssays · doi:10.1002/bies.202200150 · Cited by 34
K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target?
Nussinov, R., Muratcioğlu, S., Tsai, C., Jang, H., Gürsoy, A., & Keskin, Ö. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1135131 · Cited by 32
“Oncogenic K-Ras activates signaling pathways, including Raf/MEK/ERK, PI3K/Akt, and RalGDS.”
BackgroundNg, H. Y., Ko, J. M. Y., Yu, V. Z., Ip, J. C. Y., Dai, W., Cal, S., & Lung, M. L. (2016) · International Journal of Cancer · doi:10.1002/ijc.30034 · Cited by 30
“The link between the AKT pathway with growth factor is the transmembrane EGFR protein, which is activated when it binds to its growth factor ligands and causes subsequent activation of the downstream signaling pathway such as PI3K/ AKT.41 EGFR and its related pathway are known factors contributing to chemoresistance t…”
BackgroundInfluentialRas and Wnt Interaction Contribute in Prostate Cancer Bone Metastasis
Lin, S., Mokgautsi, N., & Liu, Y. (2020) · Molecules · doi:10.3390/molecules25102380 · Cited by 32
Shen, M., Qi, R., Ren, J., Lv, D., & Yang, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.780655 · Cited by 33
“The representative ones are the Raf–MEK–ERK and PI3K–Akt signaling networks (102, 103).”
BackgroundInteractions of melatonin with various signaling pathways: implications for cancer therapy
Mihanfar, A., Yousefi, B., Azizzadeh, B., & Majidinia, M. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02825-2 · Cited by 35
“Fekete M, Santiskulvong C, Eng C, Dorigo O. Effect of PI3K/Akt pathway inhibition-mediated G1 arrest on chemosensitization in ovarian cancer cells.”
BackgroundInfluentialAnnenkov, A. E. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8532-5 · Cited by 31
Chen, Y., Tan, K. A. L., Pang, L. Y., & Argyle, D. J. (2012) · BMC Veterinary Research · doi:10.1186/1746-6148-8-73 · Cited by 37
Advances in Targeted Therapy and Immunotherapy for Pancreatic Cancer
Liu, X., Li, Z., & Wang, Y. (2021) · Advanced Biology · doi:10.1002/adbi.201900236 · Cited by 30
de Almeida, P. D. O., Barbosa, G. D. S., Ferreira, C. C. D. S., Bernardes, L. R., Dias, R. B., Sales, C. B. S., Valverde, L. D. F., Rocha, C. A. G., Soares, M. B. P., Bezerra, D. P., et al. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109444 · Cited by 34
“The RAS family is composed of oncoproteins GTPases, that participate in the regulation of pathways involved in cell growth and motility [27].”
BackgroundDiehl, J. N., Klomp, J. E., Snare, K. R., Hibshman, P. S., Blake, D. R., Kaiser, Z. D., Gilbert, T. S. K., Baldelli, E., Pierobon, M., Papke, B., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101335 · Cited by 29
“The second best characterized KRAS effectors are PI3Ks (12).”
Endostatin inhibits the tumorigenesis of hemangioendothelioma via downregulation of CXCL1
Guo, L., Song, N., He, T., Qi, F., Zheng, S. G., Xu, X., Fu, Y., Chen, H., & Luo, Y. (2014) · Molecular Carcinogenesis · doi:10.1002/mc.22210 · Cited by 29
“Akt, interrupting the transcription and secretion of cytokines and chemokines [44].”
BackgroundK-ras Mutations as the Earliest Driving Force in a Subset of Colorectal Carcinomas
Margetis, N., Kouloukoussa, M., PAVLOU, K., Vrakas, S., & Mariolis-Sapsakos, T. D. (2017) · In Vivo · doi:10.21873/invivo.11091 · Cited by 30
McKenzie, M., Kirk, R. S., & Walker, A. J. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix654 · Cited by 28
“Although a homolog of the insulin receptor substrate adaptor protein, which in humans links IRs to downstream signaling, does not appear to exist in the S mansoni genome, PI3K could interact with such receptors directly or via alternative adaptors such as Grb2 (Smp_062950), as occurs during receptor tyrosine kinase (R…”
BackgroundTumor Suppressor Role of hsa-miR-193a-3p and -5p in Cutaneous Melanoma
Polini, B., Carpi, S., Doccini, S., Citi, V., Martelli, A., Feola, S., Santorelli, F. M., Cerullo, V., Romanini, A., & Nieri, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176183 · Cited by 44
“Among these downstream effectors, there are other molecules targeted by miR-193a-3p or miR-193a-5p: KRAS, a target of miR-193a-3p [45], and PIK3R3 and mTOR, targets of miR-193a-5p [21], which are all proteins stimulating proliferation, cell cycle progression, and cell survival in cancer cells [68,69].”
BackgroundTherapeutic Targeting of Regulated Signaling Pathways of Non-Small Cell Lung Carcinoma
Hasan, G. M., Hassan, M. I., Sohal, S. S., Shamsi, A., & Alam, M. (2023) · ACS Omega · doi:10.1021/acsomega.3c02424 · Cited by 29
Divakar, S. K. A., Reddy, M. V. R., Cosenza, S. C., Baker, S. J., Perumal, D., Antonelli, A. C., Brody, J., Akula, B., Parekh, S. S., & Reddy, E. P. (2015) · Leukemia · doi:10.1038/leu.2015.185 · Cited by 31
Senescence in pancreatic carcinogenesis: from signalling to chromatin remodelling and epigenetics
Singh, S. K., & Ellenrieder, V. (2013) · Gut · doi:10.1136/gutjnl-2012-302793 · Cited by 28
Torres, C., Mancinelli, G. E., Córdoba‐Chacón, J., Viswakarma, N., Castellanos, K., Grimaldo, S., Kumar, S., Principe, D. R., Dorman, M. J., McKinney, R. D., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1813012116 · Cited by 28
“PI3K family members play important roles as regulators of RAS-mediated cell cycle entry and cell growth, survival, and metabolism (9).”
BackgroundPortal Vein Embolization: Impact of Chemotherapy and Genetic Mutations
Deipolyi, A. R., Zhang, Y. S., Khademhosseini, A., Naidu, S., Borad, M. J., Şahin, B., Mathur, A. K., & Öklü, R. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6030026 · Cited by 27
Feng, J., Wang, X., Zhu, W., Chen, S., & Feng, C. (2017) · Biochemistry (Moscow) · doi:10.1134/s0006297917060074 · Cited by 27
“The Ras family regulates complex signaling networks by various activators and effectors, allowing them to control several cell functions, including cell proliferation, differentiation, and apoptosis [24].”
Sharma, J., Bhardwaj, V. K., & Purohit, R. (2019) · ACS Omega · doi:10.1021/acsomega.9b01439 · Cited by 28
Erdheim-Chester disease: a comprehensive review from the ophthalmologic perspective
Kanakis, M. G., Petrou, P., Lourida, P., & Georgalas, I. (2021) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2021.05.013 · Cited by 31
The role of miR-200a in mammalian epithelial cell transformation
Becker, L. E., Takwi, A. A., Lu, Z., & Li, Y. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu202 · Cited by 30
“Knockdown of miR-200a significantly inhibits doxorubicin-induced apoptosis in MCF7 cells, corroborating the results seen in the MCF10A cells (Figure 2D). miR-200a cooperates with the RalGEF Ras effector pathway Ras activity results in the activation of a wide array of downstream signaling pathways; however, the three…”
BackgroundEpidermal growth factor and aging: A signaling molecule reveals a new eye opening function
Rongo, C. (2011) · Aging · doi:10.18632/aging.100384 · Cited by 31
“Activated Ras can also activate the PI3K p110 catalytic subunit [27].”
BackgroundRole of phosphatidylinositol-4,5-bisphosphate 3-kinase signaling in vesicular trafficking
Bhattacharya, S., McElhanon, K. E., Gushchina, L. V., & Weisleder, N. L. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.10.018 · Cited by 37
Chang, C.-M., Yang, Y., Chuang, J.-H., Chuang, C.-M., Lin, T.-W., Wang, P., Yu, M.-H., & Chang, C. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112345 · Cited by 27
LvRas and LvRap are both important for WSSV replication in Litopenaeus vannamei
Tseng, Y.-T., Kumar, R., & Wang, H. (2019) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2019.02.035 · Cited by 28
Lipid Profiles of RAS Nanoclusters Regulate RAS Function
Zhou, Y., & Hancock, J. F. (2021) · Biomolecules · doi:10.3390/biom11101439 · Cited by 26
Driver Mutations in Pancreatic Cancer and Opportunities for Targeted Therapy
Olaoba, O. T., Adelusi, T. I., Yang, M. J., Maidens, T., Kimchi, E. T., Staveley-O’Carroll, K. F., & Li, G. (2024) · Cancers · doi:10.3390/cancers16101808 · Cited by 29
“The association between PI3K and the RAS-signaling pathway is embedded in the promotion of cell growth and their highly correlated oncogenic signaling [49].”
BackgroundInfluentialIdentification of ETP-46321, a potent and orally bioavailable PI3K α, δ inhibitor
Martínez, S., Hernández, A. I., Varela, C., Rodríguez-Arístegui, S., Lorenzo, M., Rodríguez, A., Rivero‐Buceta, V., Hernando, J. I. M., Saluste, C. G., Ramos-Lima, F. J., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.03.090 · Cited by 28
Chojnacka, K., Zarzycka, M., Hejmej, A., Mruk, D. D., Górowska-Wójtowicz, E., Kotula‐Balak, M., Klimek, M., & Bilińska, B. (2015) · Toxicology in Vitro · doi:10.1016/j.tiv.2015.09.027 · Cited by 27
Wang, Y., Lih, T. M., Lee, J. W., Ohtsuka, T., Hozaka, Y., Mino-Kenudson, M. A., Adsay, N. V., Luchini, C., Scarpa, A., Maker, A. V., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.08.001 · Cited by 33
Zhang, Y., Wang, Z., Ma, X., Yang, S., Hu, X., Tao, J., Hou, Y., & Bai, G. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.11.002 · Cited by 25
Lee, M.-H., Yanagawa, J., Tran, L. M., Walser, T. C., Bisht, B., Fung, E., Park, S. J., Zeng, G., Krysan, K., Wallace, W. D., et al. (2020) · PubMed · Cited by 26
Sensitivity towards HDAC inhibition is associated with RTK/MAPK pathway activation in gastric cancer
Seidlitz, T., Schmäche, T., García, F., Lee, J. H., Qin, N., Kochall, S., Fohgrub, J., Pauck, D., Rothe, A., Koo, B., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202215705 · Cited by 27
“This is interesting, as it is well established that oncogenic RAS activates besides the MAPK, the PI3K/mTOR pathway (Castellano & Downward, 2011).”
Background
Metadata
- Authors
- Castellano, E., & Downward, J.
- Affiliations
- Cancer Research UK (GB)
- Venue
- Genes & Cancer
- Publisher
- SAGE Publications
- Published
- 2011-03-01
- Volume
- 2
- Issue
- 3
- Pages
- 261-274
- ISSN
- 1947-6019 (ISSN-L)
- 1947-6027
- PMC
- PMC3128635
- OpenAlex
- W2047401805
- Cited by
- 762
- References
- 206
- Citations by year
- 2026: 32 · 2025: 38 · 2024: 50 · 2023: 52 · 2022: 48 · 2021: 82 · 2020: 69 · 2019: 59 · 2018: 50 · 2017: 43 · 2016: 55 · 2015: 54 · 2014: 42 · 2013: 45 · 2012: 37
- FWCI
- 17.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Genes & Cancer (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
- Keywords
- Ras, phosphatidylinositol 3-kinase, oncogenic KRAS, HRAS, p110α, PI3K inhibitors, Raf/MEK/ERK pathway, combination cancer therapy, tumor resistance, lung carcinogenesis, skin carcinogenesis, small GTPases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.